Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.66
LGND's Cash-to-Debt is ranked lower than
85% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. LGND: 0.66 )
Ranked among companies with meaningful Cash-to-Debt only.
LGND' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 0.62 Max: No Debt
Current: 0.66
Equity-to-Asset 0.57
LGND's Equity-to-Asset is ranked lower than
62% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. LGND: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
LGND' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.08 Max: 0.57
Current: 0.57
-0.49
0.57
Interest Coverage 3.64
LGND's Interest Coverage is ranked lower than
93% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LGND: 3.64 )
Ranked among companies with meaningful Interest Coverage only.
LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.06  Med: 3.82 Max: No Debt
Current: 3.64
Piotroski F-Score: 5
Altman Z-Score: 4.27
Beneish M-Score: -1.62
WACC vs ROIC
10.26%
2.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 40.65
LGND's Operating Margin % is ranked higher than
94% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. LGND: 40.65 )
Ranked among companies with meaningful Operating Margin % only.
LGND' s Operating Margin % Range Over the Past 10 Years
Min: -466.69  Med: -6.83 Max: 40.65
Current: 40.65
-466.69
40.65
Net Margin % -1.13
LGND's Net Margin % is ranked higher than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. LGND: -1.13 )
Ranked among companies with meaningful Net Margin % only.
LGND' s Net Margin % Range Over the Past 10 Years
Min: -359.19  Med: 8.57 Max: 2184.64
Current: -1.13
-359.19
2184.64
ROE % -0.36
LGND's ROE % is ranked higher than
75% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. LGND: -0.36 )
Ranked among companies with meaningful ROE % only.
LGND' s ROE % Range Over the Past 10 Years
Min: -1046.55  Med: 30.84 Max: 997.71
Current: -0.36
-1046.55
997.71
ROA % -0.21
LGND's ROA % is ranked higher than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. LGND: -0.21 )
Ranked among companies with meaningful ROA % only.
LGND' s ROA % Range Over the Past 10 Years
Min: -56.92  Med: 3.17 Max: 112.83
Current: -0.21
-56.92
112.83
ROC (Joel Greenblatt) % 765.47
LGND's ROC (Joel Greenblatt) % is ranked higher than
98% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. LGND: 765.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LGND' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1252.88  Med: -29.29 Max: 6370.4
Current: 765.47
-1252.88
6370.4
3-Year Revenue Growth Rate 30.40
LGND's 3-Year Revenue Growth Rate is ranked higher than
78% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. LGND: 30.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LGND' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -65  Med: 8.05 Max: 91
Current: 30.4
-65
91
3-Year EBITDA Growth Rate 46.10
LGND's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. LGND: 46.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LGND' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.7  Med: -10.3 Max: 112.5
Current: 46.1
-76.7
112.5
GuruFocus has detected 2 Warning Signs with Ligand Pharmaceuticals Inc $LGND.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LGND's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

LGND Guru Trades in Q2 2016

Joel Greenblatt 71,870 sh (+229.35%)
Columbia Wanger 202,341 sh (+28.04%)
Paul Tudor Jones 4,400 sh (+12.82%)
Ken Fisher 72,390 sh (+2.56%)
Jim Simons 116,004 sh (-0.68%)
RS Investment Management 824,750 sh (-9.62%)
» More
Q3 2016

LGND Guru Trades in Q3 2016

Ken Fisher 72,390 sh (unchged)
Jim Simons Sold Out
Columbia Wanger 123,594 sh (-38.92%)
Joel Greenblatt 38,231 sh (-46.81%)
Paul Tudor Jones 2,300 sh (-47.73%)
» More
Q4 2016

LGND Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Ken Fisher 65,490 sh (-9.53%)
Joel Greenblatt 33,965 sh (-11.16%)
Columbia Wanger 88,597 sh (-28.32%)
» More
Q1 2017

LGND Guru Trades in Q1 2017

Ken Fisher 60,390 sh (-7.79%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:PTLA, NAS:AVXS, NAS:PRTA, OTCPK:ABCZF, NAS:JUNO, NYSE:XON, NAS:TBPH, NAS:AGIO, NYSE:CBM, OTCPK:VNAPF, NAS:AAAP, NAS:DBVT, NAS:SAGE, OTCPK:MPSYY, NAS:HALO, NAS:ONCE, NAS:CBPO, OTCPK:BVNRY, NAS:SRPT, NAS:GBT » details
Traded in other countries:LGDN.Germany,
Headquarter Location:USA
Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ratios

vs
industry
vs
history
Forward PE Ratio 42.74
LGND's Forward PE Ratio is ranked lower than
85% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. LGND: 42.74 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 736.37
LGND's Price-to-Owner-Earnings is ranked lower than
98% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. LGND: 736.37 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LGND' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.54  Med: 120.11 Max: 1376.33
Current: 736.37
1.54
1376.33
PB Ratio 6.80
LGND's PB Ratio is ranked lower than
72% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. LGND: 6.80 )
Ranked among companies with meaningful PB Ratio only.
LGND' s PB Ratio Range Over the Past 10 Years
Min: 5.26  Med: 20.03 Max: 174.72
Current: 6.8
5.26
174.72
PS Ratio 22.07
LGND's PS Ratio is ranked lower than
64% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. LGND: 22.07 )
Ranked among companies with meaningful PS Ratio only.
LGND' s PS Ratio Range Over the Past 10 Years
Min: 4.63  Med: 18.05 Max: 714.32
Current: 22.07
4.63
714.32
Price-to-Free-Cash-Flow 56.53
LGND's Price-to-Free-Cash-Flow is ranked lower than
72% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. LGND: 56.53 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LGND' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 42.12  Med: 69.33 Max: 302.12
Current: 56.53
42.12
302.12
Price-to-Operating-Cash-Flow 38.38
LGND's Price-to-Operating-Cash-Flow is ranked lower than
71% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. LGND: 38.38 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LGND' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 34.63  Med: 59.85 Max: 3131.43
Current: 38.38
34.63
3131.43
EV-to-EBIT 54.81
LGND's EV-to-EBIT is ranked lower than
82% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. LGND: 54.81 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -933.3  Med: -3.5 Max: 548.4
Current: 54.81
-933.3
548.4
EV-to-EBITDA 43.65
LGND's EV-to-EBITDA is ranked lower than
78% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. LGND: 43.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -227.8  Med: -1.9 Max: 823.2
Current: 43.65
-227.8
823.2
Shiller PE Ratio 43.59
LGND's Shiller PE Ratio is ranked higher than
62% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. LGND: 43.59 )
Ranked among companies with meaningful Shiller PE Ratio only.
LGND' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.55  Med: 55.08 Max: 404.84
Current: 43.59
23.55
404.84
Current Ratio 0.72
LGND's Current Ratio is ranked lower than
91% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. LGND: 0.72 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.38 Max: 8.13
Current: 0.72
0.57
8.13
Quick Ratio 0.71
LGND's Quick Ratio is ranked lower than
89% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. LGND: 0.71 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.36 Max: 8.12
Current: 0.71
0.53
8.12
Days Inventory 172.55
LGND's Days Inventory is ranked lower than
64% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. LGND: 172.55 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 79.07 Max: 172.55
Current: 172.55
33.18
172.55
Days Sales Outstanding 49.24
LGND's Days Sales Outstanding is ranked higher than
60% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. LGND: 49.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 49.24 Max: 146.43
Current: 49.24
5.79
146.43
Days Payable 179.13
LGND's Days Payable is ranked higher than
81% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. LGND: 179.13 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 179.13  Med: 282.1 Max: 822.72
Current: 179.13
179.13
822.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.70
LGND's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. LGND: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LGND' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -36.5  Med: -8.15 Max: 0.3
Current: -0.7
-36.5
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 60.10
LGND's Price-to-Tangible-Book is ranked lower than
97% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. LGND: 60.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LGND' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.42  Med: 14.09 Max: 206.67
Current: 60.1
5.42
206.67
Price-to-Intrinsic-Value-Projected-FCF 4.12
LGND's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. LGND: 4.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LGND' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.77  Med: 5.71 Max: 7.65
Current: 4.12
3.77
7.65
Price-to-Median-PS-Value 1.22
LGND's Price-to-Median-PS-Value is ranked lower than
57% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. LGND: 1.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LGND' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 0.73 Max: 11.86
Current: 1.22
0.28
11.86
Earnings Yield (Greenblatt) % 1.80
LGND's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. LGND: 1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LGND' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 1.3 Max: 2
Current: 1.8
0.2
2

More Statistics

Revenue (TTM) (Mil) $109.0
EPS (TTM) $ -0.10
Beta1.22
Short Percentage of Float27.60%
52-Week Range $87.50 - 139.79
Shares Outstanding (Mil)20.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 120 168 210
EPS ($) 2.56 3.80 4.91
EPS without NRI ($) 2.56 3.80 4.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for LGND

Headlines

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : April 27, 2017 Apr 27 2017
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US :... Apr 26 2017
Ligand to Report First Quarter 2017 Results on May 9th Apr 13 2017
3 Stocks With Apple-Like Return Potential Apr 11 2017
Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for... Apr 05 2017
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the... Mar 28 2017
3 Least Risky Biotech Stocks on the Market Mar 28 2017
3 Stocks to Invest in Healthcare Mar 26 2017
Ligand to Participate in Upcoming Investor Conference Mar 09 2017
New Strong Sell Stocks for March 7th Mar 07 2017
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US :... Mar 07 2017
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017 Mar 01 2017
Ligand Provides Highlights from Today’s Analyst Day Event Feb 28 2017
Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene Feb 28 2017
6 Stocks on the Move With Unusual Volume Feb 28 2017
Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals,... Feb 28 2017
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27,... Feb 27 2017
Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes Feb 27 2017
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates Feb 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)